Pieris Pharmaceuticals Progresses in HER2 Gastric Cancer Development with Phase 2 Advancements
Pieris Pharmaceuticals (ISIN: US72016P1057) is garnering attention as its lead candidate, Cinrebafusp alfa, advances into phase 2 trials for HER2-positive gastric cancer, indicating potential progress in immunotherapy. Investors, particularly from…